Immunome (IMNM) CBO Horn Kinney Exercises Options, Sells 90,616 Shares

What Happened
Horn Kinney, Chief Business Officer of Immunome (IMNM), exercised a total of 90,616 option shares on 2026-08-04 (50,366 at $12.92 and 40,250 at $10.60) paying $1,077,379 in exercise price, and immediately sold those 90,616 shares in the open market for a weighted average price of $25.09, generating gross proceeds of $2,273,555 (net proceeds ≈ $1,196,176 before taxes and fees). The filing shows the exercises and the matching sale occurred the same day.

Key Details

• Transaction date: August 4, 2026; Form 4 filed August 6, 2026 (timely filing).
• Exercises (code M): 50,366 shares @ $12.92 ($650,729) and 40,250 shares @ $10.60 ($426,650).
• Sale (code S): 90,616 shares sold at weighted average $25.09 (range $25.00–$25.295) for $2,273,555. Weighted-average/range disclosed per filing (full breakdown available on request).
• Net proceeds (sale minus exercise cost): ≈ $1,196,176 before taxes, fees, or withholdings.
• 10b5-1 plan: The sales were made under a Rule 10b5-1 trading plan adopted March 30, 2026 (footnote F1).
• Vesting notes: The options exercised come from grants with standard multi-year vesting (25% vested Aug 9, 2025 and 25% vested July 29, 2026; remaining portions vest monthly over three years — footnotes F3 and F4).
• Shares owned after transaction: Not specified in the provided filing.

Context
This was an option exercise followed by an immediate market sale of the exercised shares (effectively a cashless exercise/sale). The sale was executed under a pre-established 10b5-1 plan, which typically indicates the trades were pre-planned rather than spontaneous signals of sentiment.